Trial Profile
A Phase 1/2a Clinical Trial to Evaluate the Safety and Immunogenicity of ALVAC-HIV (vCP2438) and of MF59- or AS01B-adjuvanted Clade C Env Protein, in Healthy, HIV-uninfected Adult Participants
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 10 Oct 2023
Price :
$35
*
At a glance
- Drugs ALVAC HIV vCP2438 (Primary) ; AS01B; MF 59
- Indications HIV infections
- Focus Adverse reactions; Pharmacodynamics
- Acronyms HVTN120
- 05 Oct 2023 Results published in the Journal of Infectious Diseases
- 04 Nov 2019 Status changed from active, no longer recruiting to completed.
- 09 Oct 2019 Planned End Date changed from 30 Sep 2019 to 11 Nov 2019.